|
|
The Anemia Market: Biogenerics and Second-Generation Products Drive ChangePublished by: Decision Resources Published: Mar. 7, 2007 - 16 Pages The price of this report has been reduced due to its age. The original price was $2,025 for PDF.Table of Contents
AbstractThe availability of recombinant biologic agents has revolutionized the treatment of anemia and has created a market with a small number of players. However, the inconvenient administration and high prices of these biologic agents represent an opportunity for companies to enter this market with improved alternatives.Get the Answers You Need to Shape Your Strategy Worldwide sales of erythropoiesis-stimulating proteins reached $11.2 billion in 2005, and the market has grown annually at a rate of 13.5% since 2000. Which agents are driving the growth of the anemia market in the United States, Europe, and Japan, and what recent changes have established new market leaders? Several therapies are in development for the treatment of anemia. Which emerging agents are likely to enjoy strong uptake, and which companies are likely to become key players in the anemia market? Although many older protein therapeutics have lost patent protection, the road to the launch of biogeneric products (also referred to as biosimilars) has been long and complex. What are the regulatory and manufacturing obstacles to the launch of biogenerics? Which companies are currently developing biogeneric products? The potential launch of Roche's Mircera, in development for the treatment of anemia, has sparked a legal battle with Amgen. What strategy is Amgen pursuing to block Roche's launch of Mircera in the United States, and how has Roche responded? Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||